INTEGRILIN Drug Patent Profile
✉ Email this page to a colleague
When do Integrilin patents expire, and what generic alternatives are available?
Integrilin is a drug marketed by Msd Sub Merck and is included in one NDA.
The generic ingredient in INTEGRILIN is eptifibatide. There are fifteen drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the eptifibatide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Integrilin
A generic version of INTEGRILIN was approved as eptifibatide by TEVA PHARMS USA on June 12th, 2015.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for INTEGRILIN?
- What are the global sales for INTEGRILIN?
- What is Average Wholesale Price for INTEGRILIN?
Summary for INTEGRILIN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 70 |
Clinical Trials: | 16 |
Patent Applications: | 3,909 |
Drug Prices: | Drug price information for INTEGRILIN |
What excipients (inactive ingredients) are in INTEGRILIN? | INTEGRILIN excipients list |
DailyMed Link: | INTEGRILIN at DailyMed |
Recent Clinical Trials for INTEGRILIN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Baylor College of Medicine | Phase 1/Phase 2 |
Sisse R. Ostrowski, MD PhD DMSc | Phase 2 |
University of Alabama at Birmingham | Phase 2 |
Paragraph IV (Patent) Challenges for INTEGRILIN
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
INTEGRILIN | Injection | eptifibatide | 2 mg/mL, 100 mL vial | 020718 | 1 | 2008-12-18 |
INTEGRILIN | Injection | eptifibatide | 2 mg/mL, 10 mL vial | 020718 | 1 | 2008-09-30 |
US Patents and Regulatory Information for INTEGRILIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Msd Sub Merck | INTEGRILIN | eptifibatide | INJECTABLE;INJECTION | 020718-001 | May 18, 1998 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Msd Sub Merck | INTEGRILIN | eptifibatide | INJECTABLE;INJECTION | 020718-002 | May 18, 1998 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for INTEGRILIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Msd Sub Merck | INTEGRILIN | eptifibatide | INJECTABLE;INJECTION | 020718-001 | May 18, 1998 | ⤷ Sign Up | ⤷ Sign Up |
Msd Sub Merck | INTEGRILIN | eptifibatide | INJECTABLE;INJECTION | 020718-001 | May 18, 1998 | ⤷ Sign Up | ⤷ Sign Up |
Msd Sub Merck | INTEGRILIN | eptifibatide | INJECTABLE;INJECTION | 020718-001 | May 18, 1998 | ⤷ Sign Up | ⤷ Sign Up |
Msd Sub Merck | INTEGRILIN | eptifibatide | INJECTABLE;INJECTION | 020718-002 | May 18, 1998 | ⤷ Sign Up | ⤷ Sign Up |
Msd Sub Merck | INTEGRILIN | eptifibatide | INJECTABLE;INJECTION | 020718-002 | May 18, 1998 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for INTEGRILIN
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Accord Healthcare S.L.U. | Eptifibatide Accord | eptifibatide | EMEA/H/C/004104 Eptifibatide Accord is intended for use with acetylsalicylic acid and unfractionated heparin.Eptifibatide Accord is indicated for the prevention of early myocardial infarction in adults presenting with unstable angina or non-Q-wave myocardial infarction, with the last episode of chest pain occurring within 24 hours and with electrocardiogram (ECG) changes and/or elevated cardiac enzymes.Patients most likely to benefit from Eptifibatide Accord treatment are those at high risk of developing myocardial infarction within the first 3-4 days after onset of acute angina symptoms including for instance those that are likely to undergo an early PTCA (Percutaneous Transluminal Coronary Angioplasty). |
Authorised | yes | no | no | 2016-01-11 | |
GlaxoSmithKline (Ireland) Limited | Integrilin | eptifibatide | EMEA/H/C/000230 Integrilin is intended for use with acetylsalicylic acid and unfractionated heparin.Integrilin is indicated for the prevention of early myocardial infarction in patients presenting with unstable angina or non-Q-wave myocardial infarction with the last episode of chest pain occurring within 24 hours and with ECG changes and / or elevated cardiac enzymes.Patients most likely to benefit from Integrilin treatment are those at high risk of developing myocardial infarction within the first 3-4 days after onset of acute angina symptoms including for instance those that are likely to undergo an early percutaneous transluminal coronary angioplasty (PTCA). |
Authorised | no | no | no | 1999-07-01 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for INTEGRILIN
See the table below for patents covering INTEGRILIN around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Russian Federation | 2156468 | METHOD OF ASSAY OF PRESENCE OR ABSENCE OF INHIBITORY ACTIVITY OF PLATELET AGGREGATION (PA1), PURIFIED AND ISOLATED INHIBITOR OF PLATELET ACTIVITY (PA1) AND/OR ITS TRUNCATED FORM, METHOD OF PURIFICATION OF PA1 FROM SNAKE VENOM, PHARMACEUTICAL COMPOSITION FOR PREVENTION OF THROMBUS FORMATION, METHOD OF INHIBITION OF THROMBUS FORMATION | ⤷ Sign Up |
Canada | 2636421 | UNE METHODE DE STOCKAGE DE PLAQUETTES ET DE SANG ENTIER (A METHOD OF PLATELET AND WHOLE BLOOD STORAGE) | ⤷ Sign Up |
Netherlands | 990043 | ⤷ Sign Up | |
Luxembourg | 90488 | ⤷ Sign Up | |
South Korea | 0180918 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for INTEGRILIN
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0477295 | C990043 | Netherlands | ⤷ Sign Up | PRODUCT NAME: EPTIFIBATIDE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; NAT. REGISTRATION NO/DATE: EU/1/99/109/001 - EU/1/99/109/002 19990701; FIRST REGISTRATION: CH 54050, 54054 19970227 |
0477295 | 51/1999 | Austria | ⤷ Sign Up | PRODUCT NAME: EPTIFIBATID ODER PHARMAZEUTISCH ANNEHMBARE SALZE HIEVON; NAT. REGISTRATION NO/DATE: EU/1/99/109/001 EU/1/99/109/002 19990701; FIRST REGISTRATION: LI 54050 UND 54054 19970227 |
0477295 | SPC/GB99/046 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: EPTIFIBATIDE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: CH 54054 19970227; CH 54050 19970227; UK EU/1/99/109/001 19990701; UK EU/1/99/109/002 19990701 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |